- Home
- NEGG vs JSPR Comparison
NEGG vs JSPR Comparison
Compare NEGG & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- JSPR
- Stock Information
- Founded
- NEGG 2001
- JSPR 2018
- Country
- NEGG United States
- JSPR United States
- Employees
- NEGG N/A
- JSPR N/A
- Industry
- NEGG Other Specialty Stores
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEGG Consumer Discretionary
- JSPR Health Care
- Exchange
- NEGG Nasdaq
- JSPR Nasdaq
- Market Cap
- NEGG 293.6M
- JSPR 342.2M
- IPO Year
- NEGG 2010
- JSPR N/A
- Fundamental
- Price
- NEGG $0.58
- JSPR $23.62
- Analyst Decision
- NEGG
- JSPR Strong Buy
- Analyst Count
- NEGG 0
- JSPR 10
- Target Price
- NEGG N/A
- JSPR $74.86
- AVG Volume (30 Days)
- NEGG 623.6K
- JSPR 218.3K
- Earning Date
- NEGG 12-17-2024
- JSPR 11-07-2024
- Dividend Yield
- NEGG N/A
- JSPR N/A
- EPS Growth
- NEGG N/A
- JSPR N/A
- EPS
- NEGG N/A
- JSPR N/A
- Revenue
- NEGG $1,391,833,000.00
- JSPR N/A
- Revenue This Year
- NEGG $6.01
- JSPR N/A
- Revenue Next Year
- NEGG N/A
- JSPR N/A
- P/E Ratio
- NEGG N/A
- JSPR N/A
- Revenue Growth
- NEGG N/A
- JSPR N/A
- 52 Week Low
- NEGG $0.56
- JSPR $4.00
- 52 Week High
- NEGG $1.62
- JSPR $31.01
- Technical
- Relative Strength Index (RSI)
- NEGG 41.14
- JSPR 59.51
- Support Level
- NEGG $0.62
- JSPR $22.30
- Resistance Level
- NEGG $0.64
- JSPR $23.60
- Average True Range (ATR)
- NEGG 0.04
- JSPR 1.68
- MACD
- NEGG -0.00
- JSPR 0.08
- Stochastic Oscillator
- NEGG 11.24
- JSPR 64.94
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.